Edwards Lifesciences reported second quarter 2026 sales of $1.74 billion, a 13.6% increase year-over-year, with constant currency sales growing 12.5%. Transcatheter Aortic Valve Replacement (TAVR) sales rose 11.3% to $1.26 billion, while Transcatheter Mitral and Tricuspid Therapies (TMTT) sales grew 47.3% to $195.9 million. The company reported GAAP diluted earnings per share of $0.42 and adjusted EPS of $0.78. Based on these results, Edwards increased its full-year 2026 total sales growth guidance to 10% to 11% from 9% to 11% and raised its TAVR constant currency sales growth guidance to 8% to 9%. The company is a medical device manufacturer specializing in structural heart innovation.

Edwards Lifesciences Corporation stockholders approved an amendment to the company's Long-Term Stock Incentive Compensation Program, increasing the total share pool by 7,000,000 shares to a new limit of 341,500,000 shares. The company also confirmed the election of its board of directors and the ratification of PricewaterhouseCoopers LLP as its independent auditor during the 2026 Annual Meeting.

Edwards Lifesciences Corporation has appointed Theodora Mistras as Chief Financial Officer, effective May 29, 2026, succeeding Scott B. Ullem. Ms. Mistras will receive an annual base salary of $925,000, a $2,013,000 sign-on bonus, and an initial $8,000,000 restricted stock unit award. Her compensation package also includes a target annual bonus of at least 100% of her base salary and a $4,500,000 equity award for fiscal year 2026.

Edwards Lifesciences Corporation issued a press release on April 23, 2026, announcing its financial results for the first quarter of 2026. The specific financial metrics and performance data are contained in the accompanying press release filed as Exhibit 99.1.

Edwards Lifesciences Corporation issued a press release on February 10, 2026, reporting its financial results for the fourth quarter of 2025. The specific financial metrics and performance data are detailed in the accompanying press release filed as Exhibit 99.1.

Edwards Lifesciences Corporation will not proceed with its proposed acquisition of JenaValve Technology, Inc. after a U.S. District Court granted an injunction requested by the Federal Trade Commission. The court's decision effectively blocks the transaction from moving forward.